HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Newer topical therapies for the treatment of acne vulgaris.

Abstract
Newer topical therapies approved by the US Food and Drug Administration (FDA) for the treatment of acne vulgaris are dapsone gel 5% and clindamycin phosphate 1.2% and tretinoin 0.025% combination gel. Both are formulated in aqueous-based gel vehicles. These newer topical acne products have been shown to be effective and safe in pivotal 12-week phase 3 trials and long-term studies completed over 12 months. This article reviews applicable pharmacokinetic, efficacy, and safety data reported with both products.
AuthorsJames Q Del Rosso
JournalCutis (Cutis) Vol. 80 Issue 5 Pg. 400-10 (Nov 2007) ISSN: 0011-4162 [Print] United States
PMID18189027 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Infective Agents
  • Drug Combinations
  • Keratolytic Agents
  • Clindamycin
  • Tretinoin
  • Dapsone
Topics
  • Acne Vulgaris (drug therapy)
  • Administration, Topical
  • Anti-Infective Agents (pharmacology)
  • Clindamycin (pharmacology)
  • Dapsone (pharmacology)
  • Drug Combinations
  • Humans
  • Keratolytic Agents (pharmacology)
  • Treatment Outcome
  • Tretinoin (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: